ScreenCell tracks circulating tumor cells
The French biotech company ScreenCell is developing an innovative blood filtration technology designed to improve the monitoring of solid tumors. At the heart of its approach are circulating tumor cells (CTCs), which are considered key markers of metastatic progression.
Oragen Therapeutics Simplifies Therapeutic RNA
In Besançon, a French startup is shaking up the world of innovative medicine. Oragen Therapeutics, a preclinical-stage biotech company, is developing a unique platform for the oral delivery of therapeutic RNA—a groundbreaking advancement in the treatment of chronic inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis.
AbTx: drug-conjugated immunotherapy for targeting resistant tumors
The startup AbTx, which specializes in immuno-oncology, aims to tackle the most difficult-to-treat cancers using a breakthrough technology: Antibody-Drug Conjugates (ADCs). This approach involves “delivering and targeting extremely potent chemotherapy directly to the heart of tumors,” explains Meddy El Alaoui, the company’s CEO and founder.
Videos & podcasts Biotherapies / Bioproduction
UMR RIGHT / UCPVax:
the therapeutic vaccine against cancer
What if it were possible, one day, to “vaccinate” against cancer? A team of researchers in Besançon is working to make this dream a reality. The UMR Right research unit, led by Professor Olivier Adotévi, has been developing a therapeutic vaccine called UCPVax for more than ten years.
Unlike traditional vaccines, which prevent infection, UCPVax is designed to stimulate the immune system of people who already have cancer. The idea is to teach T lymphocytes to recognize and attack cancer cells. To do this, the vaccine targets an enzyme found in almost all tumors: telomerase.
Oragen Therapeutics
Coming soon…